{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T11:26:51Z","timestamp":1783164411702,"version":"3.54.6"},"reference-count":29,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:00:00Z","timestamp":1696982400000},"content-version":"am","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jogc.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Obstetrics and Gynaecology Canada"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.jogc.2022.06.005","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T23:43:23Z","timestamp":1656546203000},"page":"1047-1053","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Low BRCA1 and BRCA2 Germline Mutation Rates in a French-Canadian Population with a Diagnosis of Epithelial Tubo-Ovarian Carcinoma"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5694-2924","authenticated-orcid":false,"given":"Juliette","family":"Bernard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wala","family":"Mehros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Gregoire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Douville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Claude","family":"Renaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Sebastianelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve-Lyne","family":"Langlais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Plante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jogc.2022.06.005_bib1","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/jnci\/djy071","article-title":"Invasive epithelial ovarian cancer survival by histotype and disease stage","volume":"111","author":"Peres","year":"2019","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.jogc.2022.06.005_bib2","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jogc.2022.06.005_bib3","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jogc.2022.06.005_bib4","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jogc.2022.06.005_bib5","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jogc.2022.06.005_bib6","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jogc.2022.06.005_bib7","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jogc.2022.06.005_bib8","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation\u2013positive women with ovarian cancer: a report from the Australian Ovarian Cancer study group","volume":"30","author":"Alsop","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jogc.2022.06.005_bib9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejca.2016.03.005","article-title":"Homologous recombination deficiency and ovarian cancer","volume":"60","author":"Ledermann","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jogc.2022.06.005_bib10","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","article-title":"Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer","volume":"5","author":"Konstantinopoulos","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jogc.2022.06.005_bib11","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.jogc.2022.06.005_bib12","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nrc2342","article-title":"DNA repair pathways as targets for cancer therapy","volume":"8","author":"Helleday","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jogc.2022.06.005_bib13","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/cncr.21536","article-title":"BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases","volume":"104","author":"Pal","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.jogc.2022.06.005_bib14","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1186\/s12885-019-6277-x","article-title":"Genetic and clinical characterization of BRCA-associated hereditary breast and ovarian cancer in Navarra (Spain)","volume":"19","author":"Ruiz de Sabando","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jogc.2022.06.005_bib15","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/jnci\/djj465","article-title":"Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada","volume":"98","author":"Risch","year":"2006","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jogc.2022.06.005_bib16","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1051\/medsci\/20072311997","article-title":"La pr\u00e9valence et la distribution des maladies g\u00e9n\u00e9tiques au Qu\u00e9bec: l\u2019impact du pass\u00e9 sur le pr\u00e9sent","volume":"23","author":"Laberge","year":"2007","journal-title":"M\u00e9decine\/Sciences"},{"key":"10.1016\/j.jogc.2022.06.005_bib17","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1034\/j.1399-0004.1999.550504.x","article-title":"Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history","volume":"55","author":"Tonin","year":"1999","journal-title":"Clin Genet"},{"key":"10.1016\/j.jogc.2022.06.005_bib18","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/jmedgenet-2018-105472","article-title":"Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap","volume":"55","author":"McCuaig","year":"2018","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.jogc.2022.06.005_bib19","doi-asserted-by":"crossref","first-page":"578.e1","DOI":"10.1016\/j.ajog.2017.06.038","article-title":"Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry","volume":"217","author":"Manchanda","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jogc.2022.06.005_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201086","article-title":"BRCA1 founder mutations and beyond in the Polish population: a single-institution BRCA1\/2 next-generation sequencing study","volume":"13","author":"Kowalik","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jogc.2022.06.005_bib21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/jmg.2006.044388","article-title":"Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer","volume":"44","author":"Simard","year":"2007","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.jogc.2022.06.005_bib22","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1136\/ijgc-2020-001261","article-title":"BRCA testing in women with high-grade serous ovarian cancer: gynecologic oncologist-initiated testing compared with genetics referral","volume":"30","author":"Piedimonte","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.jogc.2022.06.005_bib23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s10549-011-1796-4","article-title":"The BRCA2 c.9004G>A (E2003K) variant is likely pathogenic and recurs in breast and\/or ovarian cancer families of French Canadian descent","volume":"131","author":"Cote","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jogc.2022.06.005_bib24","doi-asserted-by":"crossref","first-page":"6491","DOI":"10.1038\/s41598-020-63100-w","article-title":"Founder BRCA1\/BRCA2\/PALB2 pathogenic variants in French-Canadian breast cancer cases and controls","volume":"10","author":"Behl","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jogc.2022.06.005_bib25","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/humu.23406","article-title":"Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations","volume":"39","author":"Rebbeck","year":"2018","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jogc.2022.06.005_bib26","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1002\/humu.23842","article-title":"The spectrum of BRCA1 and BRCA2 pathogenic sequence variants in Middle Eastern, North African, and South European countries","volume":"40","author":"Laitman","year":"2019","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jogc.2022.06.005_bib27","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2350-14-5","article-title":"Contribution of the PALB2 c.2323C>T [p.Q775X] founder mutation in well-defined breast and\/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent","volume":"14","author":"Tischkowitz","year":"2013","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.jogc.2022.06.005_bib28","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1200\/JCO.19.02960","article-title":"Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline","volume":"38","author":"Konstantinopoulos","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jogc.2022.06.005_bib29","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ygyno.2017.07.141","article-title":"Genetic consultation embedded in a gynecologic oncology clinic improves compliance with guideline-based care","volume":"147","author":"Senter","year":"2017","journal-title":"Gynecol Oncol"}],"container-title":["Journal of Obstetrics and Gynaecology Canada"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1701216322004224?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1701216322004224?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T15:40:34Z","timestamp":1761666034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1701216322004224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1701216322004224"],"URL":"https:\/\/doi.org\/10.1016\/j.jogc.2022.06.005","relation":{},"ISSN":["1701-2163"],"issn-type":[{"value":"1701-2163","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low BRCA1 and BRCA2 Germline Mutation Rates in a French-Canadian Population with a Diagnosis of Epithelial Tubo-Ovarian Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Obstetrics and Gynaecology Canada","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jogc.2022.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Society of Obstetricians and Gynaecologists of Canada\/La Soci\u00e9t\u00e9 des obst\u00e9triciens et gyn\u00e9cologues du Canada. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}